Immune Checkpoint Inhibitors Rechallenge After Immune-related Adverse Events

Immune Checkpoint Inhibitors Rechallenge After Immune-related Adverse Events in Patients With Cancer: an Observational and Retrospective Study Using the WHO Pharmacovigilance Database

Although immune checkpoint inhibitors (ICIs) have proved effective in treating many cancers, patients receiving ICIs may experience immune-related adverse events (irAEs). Little evidence exists on the safety of resuming these treatments after an irAE.

Our objective was to investigate the safety of ICI rechallenge after an irAE using the WHO pharmacovigilance database

Inclusion Criteria:

• Case reported in the World Health Organization (WHO) database (VigiBase) of individual safety case reports at the time of the extraction,
• consecutive individual case safety reports present in VigiBase reporting an irAEs associated to at least one immune checkpoint inhibitor.

Exclusion Criteria:

• Chronology not compatible between the drug and the toxicity.